Transdermal fentanyl: suggested recommendations for clinical use

Area of Science:

• Pain Management
• Oncology
• Pharmacology

Background:

• Transdermal fentanyl offers continuous opioid delivery for cancer pain, avoiding needles and infusion pumps.
• Initiating transdermal fentanyl may require dose titration every 24-48 hours.
• Short-acting opioids are recommended for breakthrough pain during titration.

Purpose of the Study:

• To review principles of transdermal fentanyl use in cancer pain management.
• To identify areas for further clinical research on transdermal fentanyl.

Main Methods:

• Review of established principles for chronic opioid use in cancer pain.
• Discussion of dose titration, adjuvant drug use, and continuous patient reassessment.
• Identification of needed clinical studies.

Main Results:

• Transdermal fentanyl requires careful dose titration and management of breakthrough pain.
• Established principles of chronic opioid therapy apply to transdermal fentanyl.
• Further studies are needed to compare potency, side effects, and optimal dosing strategies.

Conclusions:

• Transdermal fentanyl is a viable option for cancer pain management when administered with appropriate titration and rescue analgesia.
• Further research is essential to fully elucidate the role and optimal use of transdermal fentanyl in clinical practice.
• Comparative studies on potency, side effects, and oral transmucosal fentanyl's role are recommended.